2007
Start of the hydrogel development by prof. Marcel Karperien at the Developmental BioEngineering group of the University of Twente.
2010
High Tech Health Farm project to further develop the hydrogel technology
2011
NGI-preseed grant
Feasibility study for founding Hy2Care
2013
Research grant ReumaNederland, hydrogel implant
Market evaluation study
2013
STW valorisation grant
2014
Preclinical horse study shows ingrowth of cells within 2 weeks after implantation
Establishment of Hy2Care by inventors and support from University Twente
2015
Selection of Hy2Care as participant in a start-up bootcamp for business development
2015
Award of EFRO project
2016
Award of an SME phase 1 grant by the European Union
2017
Support of 2 Angel Investors to establish pre-clinical proof
2018
Preclinical 7 month-horse studies show groundbreaking cartilage repair
2019
Award of a €1.9M Innovation Credit for veterinary applications
2019
The Developmental BioEngineering group is appointed as Research center of Excellence by the Dutch Arthritis Society (ReumaNederland).
Series A investment round, led by Brightlands Venture Partners; joined by consortium of informal investors and supported by the Dutch Arthritis Society (ReumaNederland)
2020
Scale-up and GMP manufacture of polymers established
2021
MedFIT awards Hy2Care as the most innovative project in MedTech
2022
Hy2Care receives €6M EU funding for optimal cartilage repair
2022
Start First in Human clinical trial
2023
First in Human clinical trial, second stage, extension from UMC Utrecht to Maastricht UMC+ and Elisabeth Tweesteden Ziekenhuis Tilburg
2023
Hy2Care® receives FDA Breakthrough Device Designation for its CartRevive™ hydrogel implant
2023
Hy2Care® receives ISO 13485 certificate
